Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients

References

• Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47(Suppl 1):S32–40. doi:10.1086/590064
   PubMed Web of Science ®Google Scholar
• Delattre IK, Taccone FS, Jacobs F, et al. Optimizing beta-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 2017;15(7):677–688. doi:10.1080/14787210.2017.1338139
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083. doi:10.1093/cid/ciu027
   PubMed Web of Science ®Google Scholar
• Dhaese S, Van Vooren S, Boelens J, De Waele J. Therapeutic drug monitoring of beta-lactam antibiotics in the ICU. Expert Rev Anti Infect Ther. 2020;18(11):1155–1164. doi:10.1080/14787210.2020.1788387
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509. doi:10.1016/S1473-3099(14)70036-2
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. doi:10.1016/j.addr.2014.07.006
   PubMed Web of Science ®Google Scholar
• Petersson J, Giske CG, Eliasson E. Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients. Acta Anaesthesiol Scand. 2016;60(10):1425–1436. doi:10.1111/aas.12808
   PubMed Web of Science ®Google Scholar
• Mattioli F, Fucile C, Del Bono V, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72(7):839–848. doi:10.1007/s00228-016-2053-x
   PubMed Web of Science ®Google Scholar
• Tsai D, Stewart P, Goud R, et al. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. Int J Antimicrob Agents. 2016;48(5):542–546. doi:10.1016/j.ijantimicag.2016.08.015
   PubMed Web of Science ®Google Scholar
• Ehmann L, Zoller M, Minichmayr IK, et al. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Crit Care. 2017;21(1):263. doi:10.1186/s13054-017-1829-4
   PubMedGoogle Scholar
• Tamatsukuri T, Ohbayashi M, Kohyama N, et al. The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose. J Infect Chemother. 2018;24(10):834–840. doi:10.1016/j.jiac.2018.07.007
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272–282. doi:10.1093/cid/cis857
   PubMed Web of Science ®Google Scholar
• Jamal JA, Mat-Nor MB, Mohamad-Nor FS, et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015;45(1):41–45. doi:10.1016/j.ijantimicag.2014.09.009
   PubMed Web of Science ®Google Scholar
• Mathew SK, Mathew BS, Neely MN, et al. A nonparametric pharmacokinetic approach to determine the optimal dosing regimen for 30-minute and 3-hour meropenem infusions in critically ill patients. Ther Drug Monit. 2016;38(5):593–599. doi:10.1097/FTD.0000000000000323
   PubMed Web of Science ®Google Scholar
• Lan J, Wu Z, Wang X, et al. Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection. J Pharm Sci. 2022;111(6):1833–1842. doi:10.1016/j.xphs.2022.01.015
   PubMed Web of Science ®Google Scholar
• Onichimowski D, Bedzkowska A, Ziolkowski H, et al. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial. Pharmacol Rep. 2020;72(3):719–729. doi:10.1007/s43440-020-00104-3
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49(4):1337–1339. doi:10.1128/AAC.49.4.1337-1339.2005
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580
   PubMed Web of Science ®Google Scholar
• Briefing document pharmaceutical science and clinical pharmacology advisory committee meeting; 2019. Available from: https://www.fda.gov/media/124495/download. Accessed June 8, 2023.
   Google Scholar
• Wicha SG, Kees MG, Solms A, Minichmayr IK, Kratzer A, Kloft C. TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. Int J Antimicrob Agents. 2015;45(4):442–444. doi:10.1016/j.ijantimicag.2014.12.010
   PubMed Web of Science ®Google Scholar
• Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46(10):1171–1178. doi:10.1177/0091270006291035
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim HS, Park S, Kim HI, Lee SH, Kim YK. Population pharmacokinetics of meropenem in critically ill Korean patients and effects of extracorporeal membrane oxygenation. Pharmaceutics. 2021;13(11):1861. doi:10.3390/pharmaceutics13111861
   PubMed Web of Science ®Google Scholar
• Peng Y, Cheng Z, Xie F. Population pharmacokinetic meta-analysis and dosing recommendation for meropenem in critically ill patients receiving continuous renal replacement therapy. Antimicrob Agents Chemother. 2022;66(9):e0082222. doi:10.1128/aac.00822-22
   PubMed Web of Science ®Google Scholar
• Ehmann L, Zoller M, Minichmayr IK, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54(3):309–317. doi:10.1016/j.ijantimicag.2019.06.016
   PubMed Web of Science ®Google Scholar
• Gonçalves-Pereira PP, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15(5):R206. doi:10.1186/cc10441
   PubMed Web of Science ®Google Scholar
• Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37(4):632–638. doi:10.1007/s00134-010-2105-0
   PubMed Web of Science ®Google Scholar
• Esteve-Pitarch E, Gumucio-Sanguino VD, Cobo-Sacristan S, et al. Continuous infusion of piperacillin/tazobactam and meropenem in ICU patients without renal dysfunction: are patients at risk of underexposure? Eur J Drug Metab Pharmacokinet. 2021;46(4):527–538. doi:10.1007/s13318-021-00694-0
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50(1):73–101. doi:10.2165/00003495-199550010-00007
   PubMed Web of Science ®Google Scholar
• Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents. 2002;19(2):105–110. doi:10.1016/S0924-8579(01)00474-5
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Thengyai S, Wongpoowarak W, et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995–3001. doi:10.1128/AAC.04166-14
   PubMed Web of Science ®Google Scholar
• Chua NG, Loo L, Hee DKH, et al. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1). J Crit Care. 2022;68:107–113. doi:10.1016/j.jcrc.2021.12.013
   PubMed Web of Science ®Google Scholar
• Carlier M, Carrette S, Roberts JA, et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013;17(3):R84. doi:10.1186/cc12705
   PubMed Web of Science ®Google Scholar
• Gijsen M, Elkayal O, Annaert P, et al. Meropenem target attainment and population pharmacokinetics in critically ill septic patients with preserved or increased renal function. Infect Drug Resist. 2022;15:53–62. doi:10.2147/IDR.S343264
   PubMed Web of Science ®Google Scholar
• Parizkova RC, Martinkova J, Havel E, et al. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. Crit Care. 2021;25(1):251. doi:10.1186/s13054-021-03680-9
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015;59(9):5520–5528. doi:10.1128/AAC.00712-15
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–1545. doi:10.1007/s00134-015-4188-0
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–1305. doi:10.1164/rccm.201505-0857OC
   PubMed Web of Science ®Google Scholar
• Boonpeng A, Jaruratanasirikul S, Jullangkoon M, et al. Population pharmacokinetics/pharmacodynamics and clinical outcomes of meropenem in critically ill patients. Antimicrob Agents Chemother. 2022;66(11):e0084522. doi:10.1128/aac.00845-22
   PubMed Web of Science ®Google Scholar
• Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 2018;78(4):439–451. doi:10.1007/s40265-018-0880-z
   PubMed Web of Science ®Google Scholar
• Idoate Grijalba AI, Aldaz Pastor A, Marquet P, Woillard JB. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. Eur J Clin Pharmacol. 2019;75(10):1405–1414. doi:10.1007/s00228-019-02716-y
   PubMed Web of Science ®Google Scholar
• Lertwattanachai T, Montakantikul P, Tangsujaritvijit V, et al. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial. J Intensive Care. 2020;8:26. doi:10.1186/s40560-020-00442-7
   PubMed Web of Science ®Google Scholar
• Sornsuvit C, Wientong P, Uitrakul S, Okonogi S, Katip W. Influence of concentration and temperature on stability of imipenem focused on solutions for extended infusion. Dose Response. 2021;19(4):15593258211059325. doi:10.1177/15593258211059325
   Web of Science ®Google Scholar
• Foy F, Luna G, Martinez J, et al. An investigation of the stability of meropenem in elastomeric infusion devices. Drug Des Devel Ther. 2019;13:2655–2665. doi:10.2147/DDDT.S212052
   PubMed Web of Science ®Google Scholar
• Franceschi L, Cojutti P, Baraldo M, Pea F. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014;36(5):674–676. doi:10.1097/FTD.0000000000000054
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10):647. doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar